drugset

drugset / Trial / NCT06318676

A Study to Evaluate the Drug Levels of Mezigdomide in Adult Participants With Renal Impairment

NCT06318676 ↗

Phase 1 Completed 26 enrolled Celgene Corporation

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the drug levels of mezigdomide in participants with renal impairment.

Timeline

Start: 2024-03-21
Primary completion: 2024-11-15
Completion: 2024-11-15

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Mezigdomide	Small molecule	—	—

Indications